Liraglutide mastery course
Unit 8 of 11
In context: newer agents & regulatory status
Liraglutide did not fail; it was surpassed. Weekly semaglutide and dual-agonist tirzepatide deliver larger weight loss…
The bridge molecule in a weekly-dosing world
Liraglutide did not fail; it was surpassed. Weekly semaglutide and dual-agonist tirzepatide deliver larger weight loss with fewer injections, moving most new prescriptions away from a daily drug. Understanding exactly how they differ, and where liraglutide still competes, is essential context.
This unit compares liraglutide against the newer agents, walks its regulatory history from Victoza to generics, maps its global status, and ends with a decision-style tool for thinking through when a daily GLP-1 drug is still a reasonable choice in 2026.